Amryt Pharma
Amryt Pharma, a leading player in the pharmaceutical preparation manufacturing industry, is headquartered in Ireland (IE) and operates across various regions, focusing on innovative treatments for rare and complex diseases. Founded in 2015, the company has rapidly established itself as a key provider of specialised therapies, particularly in dermatology and metabolic disorders.
Amryt Pharma's core products, including the unique topical treatment for epidermolysis bullosa, highlight its commitment to addressing unmet medical needs. The company has achieved significant milestones, including successful product launches and strategic partnerships, positioning itself as a trusted name in the pharmaceutical landscape. With a focus on patient-centric solutions, Amryt Pharma continues to make strides in improving the quality of life for patients worldwide.
+19 vs industry average
Amryt Pharma’s score of 57 is higher than 67% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Amryt Pharma?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Pharmaceutical Preparation Manufacturing has below-average carbon intensity
Industry performance
The Pharmaceutical Preparation Manufacturing industry has reduced its overall emissions by 19% since 0
Emissions trajectory 2020 – 2021
Reported emissions
Scope 3 accounts for ••• of total emissions.
Amryt Pharma's reported carbon emissions
Amryt Pharma, headquartered in Ireland and operating within the Pharmaceutical Preparation Manufacturing industry, reported a total of approximately 368,480 kg CO2e in emissions for the year 2021. This figure represents their overall carbon footprint for that reporting period. For the preceding year, 2020, the company's emissions were approximately 441,380 kg CO2e. The provided data indicates that specific Scope 1, Scope 2, and Scope 3 emissions data are not directly available for Amryt Pharma for these years. However, the company's reporting for 2021 includes an emission factor of 1,950 kg CO2e per employee for Scope 1, and for 2020, a Scope 1 emission factor of 2,710 kg CO2e per employee was reported. Amryt Pharma's emissions data is cascaded from its ultimate parent, Chiesi Farmaceutici S.p.A. While Amryt Pharma plc is cited as the source for performance data at cascade level 0, reduction targets, specifically for SBTi and RTZ initiatives, are cascaded from Chiesi Farmaceutici S.p.A. at cascade level 1. Currently, there are no publicly disclosed specific reduction targets or achievements for Amryt Pharma itself in the provided documentation.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Amryt Pharma’s Climate Goals (2030 & 2050)
No climate goals have been disclosed for Amryt Pharma yet.
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Climate initiatives
Science Based Targets Initiative
Inherited from Chiesi Farmaceutici S.p.A.
Carbon Disclosure Project
Inherited from Chiesi Farmaceutici S.p.A.
The Climate Pledge
UN Global Compact Climate Champions initiative
Inherited from Chiesi Farmaceutici S.p.A.
RE 100
Climate Action 100
Emissions comparison with industry peers
View similar organisations
Amryt Pharma
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project